

Biliary Tract Cancers

BioBanking

Alliance A212102 NCT05334069		Blinded Reference Set for Multicancer Early Detection Blood Tests
---	--	---

Brain

NRG-BN011 NCT05095379		A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
--	--	---

Breast - Neoadjuvant

Breast - DCIS

Breast - Adjuvant Triple Negative

BREAST - Adjuvant HR Positive

BREAST - Adjuvant HER2+

Alliance A011801 NCT04457596		The CompassHER2 Trials (COMprehensive use of Pathologic Repsonse ASSEssment to optimize Therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
DFCI 21-159 ATEMPT NCT04893109		A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab vs. Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT 2.0)

Breast - Adjuvant XRT

CCTG MA.39 NCT03488693		A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
SWOG S1706 NCT03598257		A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory Breast Cancer

Breast - Metastatic

Breast - Locally Advanced/Metastatic

HER2+/HR+

DFCI 20-347 ADEPT NCT04569747		A Single Arm Phase II Study of Adjuvant Endocrine Therapy, Subcutaneous Pertuzumab, and Trastuzumab Fixed-Dose Combination for Patients With Anatomic Stage I Hormone Receptor-Positive, HER2-Positive Breast Cancer
----------------------------------	--	--

ER+/HER2-

ML43171 NCT05306340	Effective 12/22/23 must have ESR1 mutation to be eligible	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestance Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
------------------------	---	--

Triple Negative

DFCI 18-617 NCT# N/A		A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients With Early-Stage or Newly Diagnosed Metastatic Disease: The TNBC Registry
DFCI 20-166 NCT04468061		Saci-IO TNBC: Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC)

Radiation

NRG-BR007 NCT04852887		A Phase III Clinical Trial Evaluating DE-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score \leq 18 Breast Cancer
--------------------------	--	--

Children's Oncology Group Registry

APEC14B1 (Patients 25 and Younger)		Project EveryChild: A Registry, Eligibility Screening, Biology and Outcome Registry
---------------------------------------	--	---

ComboMATCH Trials

EAY191 NCT05564377		Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-N2 NCT05554354		Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial
EAY191-N4 NCT05554328		A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
EAY191-S3 NCT05554380		Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
EAY191-E4 NCT05554341	Temporarily closed to accrual	Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial
EAY191-A3 NCT05554367		Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
EAY191-A6 NCT05554367		FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations: A ComboMATCH Treatment Trial

Colorectal

NRG- GI004 NCT02997228	DTL Required	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
SWOG S1922 NCT04205968		Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
A022104 NCT05610163		The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer

Gastroesophageal

Genitourinary

Germ Cell

AGCT1531 NCT03067181 (Patients <50 years of age)		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532 NCT02585697 (Patients <= 45 years of age)		A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

GYN

NRG GY019 NCT04095364		A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin /Maintenance Letrozole vs Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
--	--	---

Head and Neck

NRG-HN009 NCT05050162		Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100mg/m ²) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40mg/m ²) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
--	--	---

Hodgkin Lymphoma

Leukemia - Untreated/Newly Diagnosed

DFCI 18-089 NCT03534323		A Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Patients or Patients with Richter's Syndrome
--	--	---

Lung Cancer - Screening Adjuvant

Alliance A151216 (ALCHEMIST) NCT02194738		Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
--	--	--

Lung Cancer - Adjuvant

Alliance A081801 NCT04267848		Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
ECOG E4512 (ALCHEMIST) NCT 02201992		A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
SWOG 1827 NCT04155034		MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Lung Cancer - 1st Line Metastatic

ECOG-ACRIN EA5163 NCT03793179		INSIGNIA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Non-squamous, Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis
--	--	--

Lung Cancer - 2nd Line Metastatic

LUNGMAP NCT03851445		A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
SWOG 1900E NCT04625647		Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
SWOG S1900G NCT05642572		A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S2302 NCT05633602		Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

Lymphoma

ANHL1931 NCT04759586		A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (Patients \geq 2 years of age)
DFCI 18-089 NCT03534323		A Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Patients or Patients with Richter's Syndrome

MCGI

MCGI 2.0		The Maine Cancer Genomics Initiative (MCGI) 2.0: A Study of Oncology Clinician and Patient Experiences with Clinical Genomics in Northern New England
-----------------	--	---

Melanoma - Locally Advanced Metastatic

ECOG-ACRIN EA6141 NCT02339571		Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
--	--	--

Melanoma - Adjuvant

Merkel Cell

Myeloma

SWOG S1803 NCT04071457		Phase III Study of Daratumumab/HuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as PostAutologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)
AFT-41 NCT04009109	Projected closed to accrual 12/21/23	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

Myeloma - Relapsed/Refractory

Prevention

Alliance A151804 NCT04242095		Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
---	--	---

Prostate

SWOG S1802 NCT03678025		Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
NRG-GU008 NCT04134260		Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

Rare Tumors

TAPUR NCT02693535		The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
----------------------	--	---

Renal

Alliance A031704 (PDIGREE) NCT03793166		PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGFTKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
--	--	--